Stance Capital LLC Makes New Investment in Stryker Corporation $SYK

Stance Capital LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 10,467 shares of the medical technology company’s stock, valued at approximately $4,141,000. Stryker makes up about 1.6% of Stance Capital LLC’s investment portfolio, making the stock its 5th largest position.

A number of other large investors have also made changes to their positions in the stock. Two Point Capital Management Inc. acquired a new position in shares of Stryker in the second quarter valued at approximately $7,281,000. Alecta Tjanstepension Omsesidigt raised its holdings in Stryker by 82.0% in the 2nd quarter. Alecta Tjanstepension Omsesidigt now owns 458,300 shares of the medical technology company’s stock valued at $181,235,000 after acquiring an additional 206,500 shares during the last quarter. SVB Wealth LLC purchased a new position in shares of Stryker during the 2nd quarter worth $4,785,000. AXQ Capital LP purchased a new position in shares of Stryker during the 2nd quarter worth $567,000. Finally, United Services Automobile Association acquired a new stake in shares of Stryker during the first quarter worth $2,857,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $353.99 on Friday. The company’s fifty day simple moving average is $366.81 and its 200-day simple moving average is $378.46. The company has a current ratio of 1.85, a quick ratio of 1.13 and a debt-to-equity ratio of 0.68. Stryker Corporation has a 52 week low of $329.16 and a 52 week high of $406.19. The company has a market cap of $135.37 billion, a PE ratio of 46.52, a P/E/G ratio of 2.51 and a beta of 0.89.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to analyst estimates of $6.04 billion. Stryker had a return on equity of 24.07% and a net margin of 12.07%.The firm’s revenue was up 10.2% compared to the same quarter last year. During the same period last year, the company posted $2.87 earnings per share. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. As a group, equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Wednesday, December 31st will be paid a dividend of $0.88 per share. This is an increase from Stryker’s previous quarterly dividend of $0.84. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Wednesday, December 31st. Stryker’s payout ratio is 44.15%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 276,173 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares in the company, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Preston Wendell Wells sold 165 shares of the company’s stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $365.88, for a total transaction of $60,370.20. Following the completion of the transaction, the chief financial officer directly owned 6,694 shares of the company’s stock, valued at approximately $2,449,200.72. The trade was a 2.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 522,118 shares of company stock valued at $185,381,932. Corporate insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $435.00 target price on shares of Stryker in a research report on Friday, November 14th. Rothschild & Co Redburn assumed coverage on shares of Stryker in a report on Thursday, September 18th. They set a “neutral” rating and a $420.00 price objective on the stock. BTIG Research restated a “buy” rating and issued a $410.00 target price on shares of Stryker in a report on Friday, November 14th. Citigroup cut their price target on shares of Stryker from $455.00 to $420.00 and set a “buy” rating on the stock in a research note on Thursday. Finally, UBS Group set a $408.00 price objective on shares of Stryker in a research note on Monday, October 13th. Twelve research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $431.83.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.